A groundbreaking discovery has emerged in the fight against pediatric ependymoma tumors, a rare and aggressive form of brain cancer. The key to unlocking a potential cure may lie in a surprising molecule called itaconate.
Ependymomas are tumors that develop in the brain or spinal cord, and they are the third most common brain tumor in children. Approximately 250 young lives are affected by this cancer each year in the United States, with the majority of cases occurring in children under the age of eight. Despite extensive research efforts, current treatments only offer temporary relief, falling short of providing a cure.
In a recent study published in Nature, researchers from the University of Michigan have identified itaconate as a critical driver in the development of ependymomas. This finding opens up new avenues for drug development, offering hope to children battling this malignant brain tumor.
More than 80% of ependymomas that originate in the upper brain regions are linked to a cancer-causing protein fusion known as ZFTA-RELA. Previous research has shown that neither ZFTA nor RELA alone can initiate cancer, but when they fuse, they become a powerful force driving tumor growth.
Cancer cells have an insatiable appetite for nutrients, and the researchers set out to uncover the metabolic changes that occur during this process. Using animal models and cell lines from mice and patients, they discovered that ependymomas produce a metabolite called itaconate. This finding was particularly intriguing because itaconate is typically produced by immune cells called macrophages in response to invading pathogens.
"We were taken aback to find that a brain tumor produces a metabolite typically made by immune cells," said Siva Kumar Natarajan, a postdoctoral research fellow in the Venneti lab.
When the researchers inhibited the enzyme ACOD1, responsible for itaconate production, in mouse models, they observed a reduction in ependymoma tumor growth. This led them to investigate further.
Using ependymoma cells, the researchers examined the impact of ACOD1 absence on gene behavior. They discovered a fascinating feedback loop between itaconate and ZFTA-RELA, where they enhance each other's activity, promoting tumor growth. This loop relies on the amino acid glutamine, which serves as a building block for itaconate synthesis.
By disrupting this loop, the researchers were able to reduce ZFTA-RELA levels and shrink the tumor in mouse models.
"This is a significant breakthrough, as it is the first study to demonstrate that the ZFTA-RELA fusion can be targeted in this type of tumor," said Sriram Venneti, M.D., Ph.D., Professor of Pathology and Pediatrics, and member of the Rogel Cancer Center and Co-Director of the Chad Carr Pediatric Brain Tumor Center.
The researchers are now expanding their study to explore similar protein fusions in other types of cancer. Additionally, they are collaborating with the Pediatric Neuro-Oncology Consortium to develop a clinical trial that targets the itaconate pathway in patients with ependymomas.
This research has the potential to revolutionize the treatment landscape for pediatric ependymoma tumors. By targeting itaconate, researchers may unlock a more effective and curative approach to this devastating disease.
But here's where it gets controversial... Should we be focusing on targeting itaconate or exploring other potential pathways? And this is the part most people miss... What if we could prevent these tumors altogether by understanding the underlying causes?
What are your thoughts on this groundbreaking research? Do you think itaconate is the key to unlocking a cure for pediatric ependymoma tumors? Share your insights and let's spark a discussion in the comments below!
